Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Optinose Inc (OPTN)

Optinose Inc (OPTN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 116,032
  • Shares Outstanding, K 112,652
  • Annual Sales, $ 70,990 K
  • Annual Income, $ -35,480 K
  • 60-Month Beta -0.24
  • Price/Sales 1.42
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade OPTN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.32
  • Most Recent Earnings $-0.09 on 03/07/24
  • Latest Earnings Date 05/09/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.11
  • Number of Estimates 3
  • High Estimate -0.09
  • Low Estimate -0.12
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +35.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8550 +13.18%
on 04/22/24
1.6400 -40.99%
on 03/25/24
-0.6623 (-40.63%)
since 03/22/24
3-Month
0.8550 +13.18%
on 04/22/24
2.1000 -53.92%
on 03/18/24
-0.4523 (-31.85%)
since 01/23/24
52-Week
0.8550 +13.18%
on 04/22/24
2.1000 -53.92%
on 03/18/24
-0.9023 (-48.25%)
since 04/21/23

Most Recent Stories

More News
OptiNose: Q4 Earnings Snapshot

OptiNose: Q4 Earnings Snapshot

OPTN : 0.9677 (-6.05%)
OptiNose: Q3 Earnings Snapshot

OptiNose: Q3 Earnings Snapshot

OPTN : 0.9677 (-6.05%)
OptiNose: Q2 Earnings Snapshot

OptiNose: Q2 Earnings Snapshot

OPTN : 0.9677 (-6.05%)
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates

OptiNose (OPTN) delivered earnings and revenue surprises of -6.25% and 15.01%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

OPTN : 0.9677 (-6.05%)
ZVRA : 4.58 (+0.22%)
OptiNose: Q1 Earnings Snapshot

OptiNose: Q1 Earnings Snapshot

OPTN : 0.9677 (-6.05%)
OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates

OptiNose (OPTN) delivered earnings and revenue surprises of -6.25% and 3.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

OPTN : 0.9677 (-6.05%)
MTEM : 1.5500 (+3.33%)
OptiNose: Q4 Earnings Snapshot

OptiNose: Q4 Earnings Snapshot

OPTN : 0.9677 (-6.05%)
Silence Therapeutics PLC Sponsored ADR (SLN) Stock Jumps 9.3%: Will It Continue to Soar?

Silence Therapeutics PLC Sponsored ADR (SLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving...

SLN : 22.51 (+0.04%)
OPTN : 0.9677 (-6.05%)
HLS Therapeutics Announces Board Appointment

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets,...

OPTN : 0.9677 (-6.05%)
MDXH : 2.45 (+4.26%)
HLS.TO : 4.75 (unch)
OptiNose (OPTN) Reports Q3 Loss, Misses Revenue Estimates

OptiNose (OPTN) delivered earnings and revenue surprises of -5.88% and 17.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

OPTN : 0.9677 (-6.05%)
EXAI : 4.38 (+3.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or ENT and allergy specialists. The company's lead product consists of XHANCE nasal polyps, XHANCE Chronic sinusitis, OPN-300, OPN- 021 and...

See More

Key Turning Points

3rd Resistance Point 1.1582
2nd Resistance Point 1.1091
1st Resistance Point 1.0384
Last Price 0.9677
1st Support Level 0.9186
2nd Support Level 0.8695
3rd Support Level 0.7988

See More

52-Week High 2.1000
Fibonacci 61.8% 1.6244
Fibonacci 50% 1.4775
Fibonacci 38.2% 1.3306
Last Price 0.9677
52-Week Low 0.8550

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar